Methylprednisolone suleptanate
Appearance
(Redirected from Promedrol)
Clinical data | |
---|---|
Trade names | Medrosol, Promedrol |
Other names | PNU-67590A; U-67590A; Methylprednisolone 21-(8-(methyl-(2-sulfoethyl)amino)-1,8-dioxooctanoate); 11β,17α-Dihydroxy-6α-methyl-21-((8-(methyl(2-sulfoethyl)amino)-1,8-dioxooctyl)oxy)pregna-1,4-diene-3,20-dione |
Routes of administration | Intravenous administration |
Drug class | Corticosteroid; Glucocorticoid |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C33H49NO10S |
Molar mass | 651.81 g·mol−1 |
3D model (JSmol) | |
| |
|
Methylprednisolone suleptanate, sold under the brand names Medrosol and Promedrol, is a synthetic glucocorticoid corticosteroid and a corticosteroid ester—specifically, the C21 suleptanate 21-(8-(methyl-(2-sulfoethyl)amino)-1,8-dioxooctanoate) ester of methylprednisolone.[1][2] It acts as a prodrug of methylprednisolone.[3] Methylprednisolone suleptanate was developed as an improved alternative to methylprednisolone acetate (Depo-Medrol) with greater water solubility for use by intravenous administration.[3]
See also
[edit]References
[edit]- ^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 811–. ISBN 978-1-4757-2085-3.
- ^ Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 675–. ISBN 978-3-88763-075-1.
- ^ a b Ferry JJ, Della-Coletta AA, Weber DJ, VanderLugt JT (November 1994). "Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers". J Clin Pharmacol. 34 (11): 1109–15. doi:10.1002/j.1552-4604.1994.tb01988.x. PMID 7876403. S2CID 40533592.
External links
[edit]